Full-Time

Head of Packaging and Labeling

Confirmed live in the last 24 hours

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

Compensation Overview

$215.6k - $323.3k/yr

+ Bonus + Equity Awards

Senior, Expert

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

Hybrid position allows for remote work up to two days per week.

Category
Biology Lab & Research
Biology & Biotech
Required Skills
Management
Business Strategy
Requirements
  • Experience in one or multiple packaging disciplines including materials and closure systems, design of secondary and tertiary components, component compatibility, component qualification, equipment installation and qualification
  • Experience supporting packaging for pharmaceutical products from research through registration and launch
  • Experience supporting packaging across pharmaceutical dosage forms and across modalities
  • Experience in building and managing a complex global technical/packaging capability
  • Expert understanding of the principles and regulations associated with GMP products and processes
  • A results-oriented leader with a sense of urgency to deliver quality results in a highly ethical and professional manner
  • Excellent communication and interpersonal skills with the ability to communicate complex issues and solutions enterprise-wide
  • Ability to anticipate adverse scenarios and provide contingency plans to address them
  • Sound judgment and business acumen with personal versatility and flexibility as the business and team evolves
  • Bachelor's Degree in Packaging, Chemical, Mechanical, Material Engineering, or a relevant discipline
  • Typically requires 15 years of experience, or the equivalent combination of advanced education and experience, including 7 years of leadership/management experience.
Responsibilities
  • Leads the P&L organization across modalities, responsible for multiple technical areas and leverages knowledge to build alignment across technical areas or functions
  • Provides leadership to resolve critical issues impacting manufacturing operations in collaboration with relevant stakeholders
  • Responsible for supporting global launches of new products and driving efficiencies throughout the product lifecycle
  • Supports Regulatory on CMC strategy and market applications, and represents Vertex to global regulatory agencies
  • Represents MS&T on corporate and strategic teams (e.g. supplier partnerships) and long-range planning process
  • Defines strategy and champions effective continuous improvement of manufacturing operations
  • Recruits, directs, motivates and develops teams, maximizing contribution, professional growth and ability to build and sustain a high-performing workforce
  • Designs and implements functional/department goals; contributes to the development of operational strategy and develops annual business plans to ensure alignment
  • As a people manager within the organization, may have financial accountabilities and human resource responsibilities for assigned staff
  • Ability to travel domestic and international (approximately 30%)
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex's partnership with Orna could lead to breakthroughs in gene therapy solutions.
  • Recent investments indicate strong investor confidence in Vertex's strategic direction.
  • Vertex's reaffirmed stock rating suggests stability and potential for steady growth.

What critics are saying

  • Increased competition in cystic fibrosis treatments could impact Vertex's market share.
  • High costs of gene-editing therapies may limit their commercial success.
  • Regulatory challenges could delay approvals for Vertex's new gene-editing therapies.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • Partnerships with Arbor and Orna enhance Vertex's gene-editing and cell therapy capabilities.
  • Vertex's innovative R&D approach sets it apart in the biotechnology industry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

Slater Sentinel
Mar 23rd, 2025
Stevens Capital Management LP Makes New $829,000 Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Stevens Capital Management LP makes new $829,000 investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Investing.com
Mar 20th, 2025
BMO maintains Vertex stock Market Perform rating and $41 target

The reaffirmation of the rating and target came after Vertex held its first analyst day since its initial public offering in 2020.

Stat News
Mar 18th, 2025
Genetics expert is first NIH director to leave under Trump

He will be replaced on an interim basis by Director Ian Smith, a former Vertex Pharmaceuticals executive.

GlobeNewswire
Mar 18th, 2025
Arbor Biotechnologies Announces $73.9 Million Series C Financing to Advance Novel Gene Editing Therapeutics

Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investors Financing extends Arbor’s cash runway into...

MarketBeat
Feb 14th, 2025
JSF Financial LLC Invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

JSF Financial LLC invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).